This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Levetown & Jenkins, LLP Announces An Investigation Of The Acquisition Of King Pharmaceuticals, Inc. By Pfizer, Inc.

Levetown & Jenkins, LLP is conducting an investigation into alleged breaches of fiduciary duties and violations of state law by King Pharmaceuticals, Inc. (“King”) (NYSE: KG) and its Board of Directors in conjunction with the proposed buyout and acquisition of King by Pfizer, Inc. (NYSE: PFE). Under the terms of a merger agreement announced on October 12, 2010, King shareholders will receive $14.25 in cash for each share of King common stock they hold. The transaction is valued at approximately $3.6 billion.

The firm’s investigation concerns whether the proposed acquisition properly values King. Specifically, the investigation seeks to determine whether the King Board of Directors engaged in a fair process to obtain adequate consideration for all of the company's shareholders, whether the transaction undervalues the company to the detriment of its shareholders and, if so, the extent to which the company is undervalued in the proposed transaction.

Levetown & Jenkins, LLP is a national law firm comprised of former federal and state prosecutors with extensive experience in the investigation and prosecution of shareholder fraud. The firm specializes in the representation of investors in shareholder and securities fraud class actions. If you currently own shares of King and wish to obtain additional information about your rights as a shareholder, please contact Michael T. Harrison, Esq. at 713-392-7465 or mharrison@levjen.com. For more information about the firm, please visit www.levjen.com.

Attorney Advertising. (C) 2010 Levetown & Jenkins, LLP. The law firm responsible for this advertisement is Levetown & Jenkins, LLP ( www.levjen.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We are happy to discuss your particular case.

Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG

Markets

DOW 17,841.98 -86.22 -0.48%
S&P 500 2,080.15 -9.31 -0.45%
NASDAQ 4,919.6440 -19.6830 -0.40%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs